RiMO-301

DRUG3 trials

Sponsors

Coordination Pharmaceuticals, Inc., University of Illinois at Chicago

Conditions

Advanced TumorsHead CancerHead Neck CancerHead and Neck CancerIntratumoral InjectionNeck Cancer

Phase 1

Phase I Study of RiMO-301 With Radiation in Advanced Tumors

CompletedNCT03444714

Coordination Pharmaceuticals, Inc.Advanced Tumors

Start: 2018-04-10End: 2025-06-16Updated: 2025-09-15

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

RecruitingNCT05838729

Coordination Pharmaceuticals, Inc.Head Neck Cancer, Intratumoral Injection

Start: 2023-04-03End: 2026-12-31Target: 16Updated: 2025-09-17

Phase 2

RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

Not yet recruitingNCT07732634

University of Illinois at ChicagoHead and Neck Cancer, Head Cancer, Neck Cancer

Start: 2026-08-01End: 2031-08-01Target: 20Updated: 2026-07-29

Related Papers

A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.

Journal of Clinical Oncology2023-06-0135 citations